Yeztugo (lenacapavir) is an HIV-1 capsid inhibitor that is administered every 6 months after an initial dosing regimen.

The Statistical Center for HIV/AIDS Research and Prevention (SCHARP), located at Fred Hutch Cancer Center, is a statistical and data management center (SDMC) dedicated to supporting investigators who ...

In a study of human immune cells infected with HIV, the virus that causes AIDS, scientists at Johns Hopkins Medicine say a ...

Lenacapavir, created by Foster City-based Gilead Sciences, has been in use for several years as a treatment for HIV/AIDS ...

It can take HIV symptoms years to appear—sometimes even longer—after infection. But within a month or two of HIV entering the body, 40% to 90% of people experience symptoms known as acute retroviral ...

The US Food and Drug Administration (FDA) has approved lenacapavir, an injectable drug that offers long-lasting protection ...

The FDA has approved Yeztugo (lenacapvir), a twice-yearly injection to prevent HIV infection that could improve adherence ...